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Abstract
Hepatic adenoma is known as a benign lesion encountered mainly in female 
patients and classically linked to the administration of oral contraceptives. In the 
last decade, the risk factors for its occurrence have changed and so did the sex 
ratio. The histopathological classification of hepatic adenomas was found to be 
related with certain genetic mutations that determine the risk for malignancy. The 
diagnosis of hepatic tumor is correlated with clinical and imaging data in an effort 
not only to rule out other tumors but also to distinguish the subtype of adenoma, 
which is very important for the management of the patient. The ultimate diagnosis 
is established by pathologists by routine histopathological and specific immunohis-
tochemical staining. There are two major issues that pathologists need to recognize: 
the presence of β-catenin gene mutation and/or malignant degeneration. The best 
imaging examination is considered to be MRI. However, along with MRI, ultra-
sound and computer tomography have proved themselves to be effective not only in 
evaluating the number, size, localization, and complications of hepatic adenomas, 
but also in identifying their subtype. A detailed presentation of characteristics of 
all groups of hepatic adenoma is provided. The means of management of hepatic 
adenomas are documented and decisional algorithm is explained, based on certain 
criteria.
Keywords: hepatic adenoma, hepatocellular adenoma, liver adenoma, adenomatosis, 
hepatectomy, laparoscopic hepatectomy, liver transplantation, liver imaging
1. Introduction
Hepatic adenoma (HA) is a rare, benign tumor of epithelial origin (2% of all 
liver tumors [1]) that develops usually in healthy liver [2] and is known to occur 
mainly in young female patients, having been linked to the prolonged use of oral 
contraceptives [3]. In Europe and North America, it has an incidence of 3/100,000/
year [4]. Even though multiple hepatic adenomas have been described in the litera-
ture, this is a rare occurrence, most of the adenomas being solitary (70–80%), and 
thus, often asymptomatic unless they become complicated (voluminous adenomas 
causing upper quadrant pain and/or rupture of the tumor with hemoperitoneum 
and malignant transformation) [5]. Hepatocellular adenoma is a term sometimes 
used instead of hepatic adenoma, being correct in contradiction to liver adenoma 
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or liver cell adenoma, which are less desirable because these two can also include 
the bile duct adenoma [6]. Even though the prognosis of this type of tumor is 
not well established, it is important to differentiate it from other hepatic tumors 
since the hepatic adenoma has a particular therapeutic management. Differential 
diagnosis however can be challenging, but can be achieved preoperatively by imag-
ing techniques. Positive diagnosis is a histopathological one and is often obtained 
postoperatively [7].
2. Epidemiology
The incidence of HA has increased in recent years, but at the same time, imaging 
techniques have improved, and therefore, this higher incidence might be explained 
by the better diagnostic techniques nowadays available. Also, in recent years, it 
seems to be a change in epidemiology, as more cases of HA in male patients are 
described, particularly in Europe and Asia. This may be caused by an increased inci-
dence of obesity, another recognized risk factor of HA. Moreover, in recent years, 
more and more cases of malignant transformation of HA have been reported, and 
this also might be a result of improved histopathological diagnosis.
Although the link between HA and use or oral contraceptive in women of child-
bearing age is maintained, recent studies have shown other emerging important risk 
factors such as metabolic syndrome [8].
3. Risk factors
The most important risk factor seems to be the use of oral contraceptives. 
Hepatic adenoma used to be exceptionally rare before the age of oral contraceptives, 
but after these became popular as a contraceptive solution, more and more cases 
of HA were reported. In women who were long-time users of oral contraceptives, 
the incidence was 1 in 30–40,000, whereas in women who have never used oral 
contraceptives, the incidence was 1 in 1 million, which proves a strong link between 
these two. Hepatic adenomas in women with prolonged use of oral contraceptives 
tend to be more numerous, more voluminous, and with a higher risk of spontaneous 
rupture and bleeding [9–12].
Another important risk factor that became even more important than other 
known risk factors, such as glycogen storage diseases and diabetes mellitus type 2 
alone, is the metabolic syndrome. Obesity is more and more prevalent in the general 
population, and thus, it became a more important risk factor in this pathology. 
Weight loss should be considered as the first therapeutic option in the management 
of HA in obese patients [13]. A recent study has proved that bariatric-induced 
weight loss results in significant regression of HA in severely obese women, which 
emphasizes the role of overweight in HA pathophysiology [14]. Even more so, 
patients with metabolic syndrome and hepatic adenomas seem to be associated 
with a higher rate of malignization [8]. The association between oral contraceptive 
use and metabolic syndrome on one hand and HA on the other tends to prove an 
important hormonal sensitivity of the tumor (obesity is associated with higher 
estrogen levels), and this is supported by the fact that adenomas may stop their evo-
lution or even regress as a result of oral contraceptive cessation [15]. In spite of this, 
immunohistological studies failed to prove the direct effect of these hormones via 
steroid receptors in normal and adenomatous hepatic tissue, and so the mechanism 
by which high estrogen levels may cause an adenomatous transformation is still 
incompletely understood [16]. As a hyperestrogenic state, pregnancy has also been 
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incriminated as a risk factor, and there have been many reports of ruptured HAs in 
pregnant patients with a very high mortality for both mother and child [16–19].
Apart from estrogen, use of anabolic androgens has also been linked to a higher 
incidence in HAs, which is being proved not only in body builders but also in 
patients treated with steroids for Fanconi syndrome, aplastic anemia, etc. Cessation 
of steroid use has also been linked to regression in size of HAs [15].
Hepatic adenoma has also been linked to glycogen storage disease and hepato-
cyte nuclear factor 1A maturity onset diabetes of the young (HNF1A MODY). The 
incidence is 51% in patients with type I glycogen storage disease and 25% in those 
with type III glycogen storage disease (GSD) [8]. Hepatic adenoma in GSD occurs 
before the age of 20 years, is more common in males, and is typically multiple. 
Dietary therapy and correction of insulin, glucose, and glucagon levels have been 
proved to lead to regression of adenomas [15]. The mechanism by which GSD is 
involved in the development of HA is also unknown.
Finally, there seems to be a genetic predisposition, and nowadays, HAs are 
believed to result from specific genetic mutations involving TCF1 (transcription 
factor 1 gene), IL6ST (interleukin 6 signal transducer gene), and CTNNB1  
(β catenin-1 gene) [20].
4. Pathology
HAs present as solitary lesions in most cases (70–80%), although multiple 
adenomas can exist of variable sizes. HAs usually occur in the right hepatic lobe. 
Macroscopically, HAs present as a smooth, tan-colored lesion, well demarcated 
from the normal hepatic tissue in spite of not having a capsule, often with areas 
of hemorrhage and necrosis (Figure 1). Large blood vessels that surround it are 
the source of hemorrhage in a complicated adenoma. The lack of a fibrous capsule 
means that the bleeding can extend into the liver parenchyma unrestricted.
Microscopically, adenomas are made of adenoma cells, which are typi-
cally larger than normal hepatocytes and contain glycogen and lipid inclusions 
(Figures 2 and 3). The nuclei are small and regular and mitoses are infrequent. 
The normal architecture of hepatic tissue is severely disrupted, with no portal 
tracts of bile ducts, while adenoma cells are disposed in trabeculae interspersed 
with arteries and thin-walled blood vessels and sinusoids. The absence of bile 
ducts is a notable feature that helps in the differential diagnosis of HA with non-
neoplastic liver tissue and focal nodular hyperplasia. Kupffer cells may only rarely 
be present in HA.
Figure 1. 
Resected specimen after mesohepatectomy for a large IHA.
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Similarities with a well differentiated hepatocellular carcinoma (Edmonson I) 
makes the differential diagnosis a challenging one.
Based on an extensively characterized clinical, morphological, phenotypical, 
and genotypical profile, four distinct subtypes of HA have been identified [3, 21]:
1. Hepatocyte nuclear factor-1 (HNF-1)—mutated HAs (H-HA)
2. β-Catenin-mutated hepatic adenomas (β-HA)
3. Inflammatory hepatic adenomas (which harbor mutations involving the 
interleukin-6 signal transducer) (IHA)
4. Unclassified hepatic adenomas (U-HA).
Inflammatory and HNF1-mutated hepatic adenomas are the most frequent 
subtypes (80%).
The first group (H-HA) comprises 35–40% of all patients and almost exclusively 
includes women. It is related to the presence of transcription factor 1 gene muta-
tions that inactivate hepatocyte nuclear factor 1α (HNF-1α). The nonfunctioning 
HNF-1α protein promotes lipogenesis and hepatocellular proliferation. Moreover, 
abnormal HNF-1α protein determines silencing of liver fatty acid-binding protein 
FABP1. FABP1 is a gene positively regulated by HNF-1α and expressed in normal 
Figure 2. 
Normal liver (left) and hepatocellular adenoma (right), HE ×40.
Figure 3. 
Hepatocellular adenoma—benign hepatocytes (large, clear, and pale due to accumulation of glycogen) 
arranged in plates, cords, and sheets, HE ×200.
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liver tissue, but in H-HA its downregulation results in impaired fatty acid traf-
ficking in hepatocytes, which causes intracellular fat deposition [22]. H-HA is 
sometimes associated with maturity-onset diabetes of the young (MODY), type 3, 
and familial hepatic adenomatosis. Half of these patients have multiple HAs. More 
than 90% have a history of oral contraceptive use. The tumors are characterized 
by marked steatosis (Figures 4–7), a very low risk of complications, and a low 
risk of malignant transformation. On immunohistochemistry staining, H-HA is 
LFABP (liver fatty acid binding protein) negative, which is in contrast with normal 
expression in the surrounding nontumoral liver [21]. The sharp contrast between 
tumor and adjacent parenchyma in terms of steatosis and LFABP expression enables 
delineation of tumor borders which are often irregular and lobulated with often 
small HA foci in vicinity.
The second group comprises 10–15% of all patients, includes mainly men, and 
is characterized by the presence of mutations that activate β-catenin and cellular 
abnormalities. β-Catenin is encoded by catenin β 1 gene (CTNNB1) on chromo-
some 3p21 and represents an important downstream effector of the Wnt/β-catenin 
pathway. This pathway is important in liver embryogenesis, cell adhesion, growth, 
zonation, and regeneration [22]. An activating β-catenin mutation is also associated 
with specific conditions such as glycogen storage disorders or androgen administra-
tion. The phenotype is represented by cellular atypia with high nuclear-cytoplasmic 
ratio, nuclear atypia, and pseudoglandular growth pattern. It is identified by 
immunohistochemistry due to a strong expression of glutamine synthetase with or 
without aberrant cytoplasmic and nuclear expression of β-catenin. β-HA has the 
highest risk of malignant transformation than other HA subtypes, and it is very 
difficult to be distinguished from the well-differentiated hepatocellular carcinoma 
(HCC). Some risk factors are related to β-HA, such as male hormone administra-
tion, glycogenosis, and familial polyposis.
The third group (IHA) includes 50% of all patients and is most common in 
overweight women who suffer from metabolic syndrome or have had prolonged 
estrogen exposure. Patients with IHA demonstrate both serum and lesional indi-
cators of an active inflammatory response. IHA is characterized histological by 
inflammation, marked sinusoidal dilatation or congestion, numerous thick-walled 
arteries, and ductular reaction (Figures 8 and 9). This subgroup was previously 
named ‘telangiectatic focal nodular hyperplasia.’ The extent of congestion, peliosis, 
and hemorrhage is different from case to case. Steatosis may be present in IHA but 
is not as extensive as in H-HA. In case of multiple tumors, the amount of steatosis 
Figure 4. 
Hepatocellular adenoma—HNF1 alpha mutated subtype—steatosis within the tumor, HE ×200.
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varies among the tumors in the same patient. Immunohistochemically, it is distinc-
tive by a strong expression of inflammation-associated proteins such as serum 
amyloid A and C-reactive protein at mRNA and protein levels. The genetics of this 
Figure 7. 
Hepatocellular adenoma—steatosis within the tumor, HE ×200.
Figure 5. 
Hepatocellular adenoma—HNF1 alpha mutated subtype—steatosis and pseudoglandular formations, 
HE ×200.
Figure 6. 
Hepatocellular adenoma—HNF1 alpha mutated subtype—pseudoglandular formations and steatosis within 
the tumor, HE ×200.
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group is related to activation of the JAK/STAT pathway underlined by mutations 
in different genes. In 60%, there are somatic gain-of-function mutations of the 
interleukin-6 signal transducer gene (IL6ST), which is located at chromosome 5q11 
and encodes for glycoprotein 130. Gain-of-function mutations in glycoprotein 130 
activate JAK–STAT-3 without interleukin-6 binding. The other 40% show overex-
pression of wild-type glycoprotein 130, which activates STAT-3 through an uniden-
tified mechanism. Marked peliosis is probably caused by suppression of albumin 
gene, insulin-like growth factor gene IGF1, and/or transthyretin gene. Mutations of 
β-catenin may coexist in 10% of IHA (β-IHA). These patients may have signs and 
symptoms of systemic inflammatory syndrome, manifested as fever, leukocytosis, 
and elevated serum levels of CRP. Abnormal results of liver function tests may 
occur, with elevation of alkaline phosphatase and γ-glutamyl transferase. Systemic 
AA amyloidosis is a rare complication of HA which causes nephrotic syndrome with 
deteriorating renal function. Resection of the tumor is followed by improvement in 
renal function and a marked decrease of the serum concentrations of acute phase 
proteins [23].
The last group that is unclassified (UHA) accounts for 5–10% of adenomas. For this 
group, the genotype is unknown and the phenotype and immunohistochemistry—
unspecific. In this group is also included HA that cannot be classified due to near-total 
necrosis or hemorrhage [21].
The first important thing for the pathologist is to correctly identify the 
β-catenin-activated HA and to decide when immunostaining is needed. Morphology 
Figure 8. 
Hepatocellular adenoma—inflammatory subtype, HE ×200.
Figure 9. 
Hepatocellular adenoma—inflammatory subtype, HE ×40, with sinusoidal dilatation and hemorrhage within 
the tumor.
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and additional immunohistochemical markers can discriminate between different 
types of HA in more than 90% of cases [24]. Identification of beta-catenin positive 
adenomas has important implications in the decision for surveillance and treat-
ment of these patients. Even if very specific, nuclear β-catenin immunostaining is 
of low sensitivity in accurate detection of β-HA and β-IHA due to uneven staining 
distribution or focal nuclear staining. Therefore, additional molecular biology is 
required. It is recommended to perform glutamine synthetase (GS) staining on 
every single HA, because GS is one of the target genes in case of β-catenin activa-
tion, and it is usually diffusely and strongly expressed in β-catenin-activated 
HA. GS staining can also be patchy or diffuse but less intense and still be an indica-
tion of β-catenin-activating mutations, but in this case, a molecular analysis must 
be performed to confirm it.
The second important thing for the pathologist is to correctly recognize foci 
of HCC inside HA. The problem is to avoid overdiagnosis in case of mild or focal 
cellular atypia. Some HAs may look worrisome due to the presence of architectural 
distortion, thicker liver cell plates, extensive pseudogland formation, and decreased 
reticulin framework together with increased CD34 staining (Figure 10). These 
are called “atypical HA,” “borderline lesions,” and, recently, “well-differentiated 
hepatocellular neoplasms of uncertain malignant potential.” Reticulin staining 
(Figure 11) is the most powerful tool to identify foci of definite malignant trans-
formation, especially in association with architectural distortion, cellular atypia, 
and increased CD34 staining. Glypican 3 is also very useful when it is positive 
(Figure 12), but its negativity does not rule out malignancy [25]. In most cases of 
HA and occasionally in HCC, the CD34 staining intensity is variable in different 
areas and virtually all HCCs have homogenous CD34-positive staining intensity and 
density [26]. Total loss of reticulin network and diffuse increased CD34 expres-
sion, possible presence of glypican 3, and increased MIB1 staining are indications 
for HCC foci. HSP70 can be also useful. There is no specific phenotype of HCC 
developed from HA, but some observed that these HCC are often pigmented or 
cholestatic.
The pathologist needs enough samples, some of them at the junction with the 
nontumoral liver. For immunohistochemical results, it is mandatory to have a 
biopsy of the nontumoral liver for comparison.
Interestingly, certain magnetic resonance imaging (MRI) features seem to 
correlate with the histologic subtypes, suggesting that it may be possible to classify 
them by MRI [7]. HNF1-inactivated HA and inflammatory HA can particularly be 
diagnosed by radiologists with considerable accuracy.
Figure 10. 
Hepatocellular adenoma—CD34 immunohistochemical stain for endothelial cells, few sinusoids are seen in the 
tumor, ×200.
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4.1 Adenomatosis
Adenomatosis is a distinct clinical entity and was first described in 1985 [27] and 
since then has been defined by the presence of more than 10 adenomas, involving 
both hepatic lobes, in the absence of glycogen storage diseases, prolonged use of 
steroids, or resolution with steroid cessation [28]. It is estimated that adenomatosis 
affects both men and women, and, unlike HA, is correlated with a higher risk of 
impaired liver function, manifested as an increase in serum alkaline phosphatase 
and GGT levels [27] and also with a higher risk of bleeding. Instead, the malignant 
degeneration does not correlate with the number of lesions. There are two dif-
ferent patterns of adenomatosis: (1) the massive pattern, which is defined by the 
existence of larger lesions, up to 10 cm, that often result in gross hepatomegaly with 
deformed contour of the liver and (2) the multifocal pattern, which is character-
ized by smaller lesions, with diameter less than 4 cm, that rarely deform the liver, 
but has a tendency to progress fast and become symptomatic [29]. The etiology of 
hepatic adenomatosis is suspected to be linked to congenital or acquired abnor-
malities of hepatic vasculature. In a study of 15 patients with adenomatosis, 5 had 
abnormalities in hepatic vasculature: congenital absence of portal vein, portal 
venous thrombosis with cavernous modification, and intrahepatic portosystemic 
shunts [1, 30].
Figure 11. 
Hepatocellular adenoma—reticulin stain—left normal liver and right hepatocellular adenoma—there is no 
loss of reticulin network, Gomori ×200.
Figure 12. 
Hepatocellular adenoma—HNF1 alpha mutated subtype—mild lipofuscin deposits revealed by glypican 3 
immunohistochemical stain, ×200.
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The conditions that predispose to adenomatosis and evolution of the disease 
are poorly understood, since the medical literature reports only information in 
regard to individual cases or small case series, but some similarities with the HA 
are evident: the tendency toward hemorrhage (especially in adenomas larger than 
4 cm) and the risk of malignant transformation. Adenomas in hepatic adenomatosis 
may be of inflammatory, hepatocyte nuclear factor 1 alpha mutated, or beta-catenin 
mutated subtype.
5. Signs and symptoms
Most commonly, HA goes unnoticed due to its lack of signs and symptoms, 
but when it does become symptomatic, it is either due to its increase in volume, 
tumor necrosis, or complications such as life-threatening intra-abdominal bleed-
ing due to spontaneous rupture of the highly vascularized tumor. Sudden, severe 
pain with hypotension in a patient with HA indicates rupture into the perito-
neum, an event associated with a mortality of up to 20 percent if not identified 
and/or treated accordingly [9, 31, 32]. The risk of bleeding is difficult to estimate 
overall, but it is quite high in patients with symptomatic HAs (25–64%). Tumor 
size that exceeds 35 mm has been associated with an increased risk of bleeding 
[33]. The risk of bleeding depends on the localization of the tumor. Exophytic 
lesions (protruding from liver) had the highest risk of bleeding (67%), followed 
by subcapsular ones (19%) and at last intrahepatic HA (11%). Lesions in seg-
ments II and III had more bleeds than those in the right liver (34% versus 19%). 
The visualization on imaging of peripheral or central arteries represents a risk 
of bleeding comparative with no visible vascularization in the lesion [33]. Also 
a long history of contraceptive use and recent hormonal use are risk factors for 
bleeding from HA. Young age seems to be associated with an increased incidence 
of HA rupture, independent of hormonal treatment duration, suggesting a 
need for careful surveillance or prophylactic treatment in this population [34]. 
Bleeding is graded as intratumoral (grade I), intrahepatic (grade II), or extra-
hepatic (grade III) and represents a potentially life-threatening complication in 
patients with HAs.
Hepatic adenomas are diagnosed when they cause epigastric or upper quadrant 
pain or during an imaging study done for unrelated ailments, and less commonly 
when an abdominal mass is palpated on clinical examination. When HA is suffi-
ciently large and compresses bile ducts, jaundice may become another sign.
6. Diagnosis and differential diagnosis
There are no specific serologic markers or laboratory findings for HA, but cer-
tain findings can lead the diagnosis away from an adenoma and toward a liver cell 
carcinoma in case of an increased serum alpha-fetoprotein, or toward a metastasis 
in the case of increased serum tumor markers for digestive tract tumors [35].
The definite diagnosis in this pathology is naturally a histological one; however, 
obtaining it preoperatively means making a biopsy from a fragile and highly vas-
cular tissue, with significant risk of bleeding. Having to deal with a benign lesion, 
and given the fact that the amount of tissue obtained is rarely enough or suitable 
for a diagnosis, this risk is not justified. Thus, the diagnosis of this tumor is based 
on analyzing a combination of epidemiologic and clinical data and imaging stud-
ies, but often the confirmation of the diagnosis is done by the pathologist, after the 
hepatic resection.
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Usually a HA is suspected in a young adult with a singular and asymptomatic 
hepatic lesion, but a thorough differential diagnosis should be made and often this 
proves to be difficult. The differential diagnosis between adenomas and focal nodu-
lar hyperplasia is usually challenging, but can be done, most of the times, based on 
imaging characteristics.
6.1 Imaging in liver adenomas
Imaging in adenomas includes mostly ultrasound, contrast-enhanced ultra-
sound (CEUS), multislice computer tomography (MSCT), and magnetic resonance 
imaging (MRI) (Figure 13).
6.1.1 Ultrasound
The most accessible, cost-friendly, and probably responsible for most discover-
ies of asymptomatic HA is the ultrasound, even though it cannot distinguish it from 
other liver tumors. On gray scale ultrasound, HA is seen as a well-defined solid, 
echogenic mass, but sometimes as complex hyper/hypoechoic, heterogeneous mass 
with anechoic areas due to fat, hemorrhage, necrosis, and calcifications; a capsule 
may also be seen [36]. Color Doppler US can aid in the distinction from FNH in the 
absence of a central arterial signal, FNH having characteristic intratumoral and 
peritumoral vessels [37, 38]. Contrast-enhanced ultrasound with sulfur hexafluo-
ride microbubbles (SonoVue or Lumason) greatly improves diagnosis as compared 
to US without contrast.
6.1.2 Computer tomography
One of the most accurate imaging tools in diagnosing a HA is contrast enhanced 
computed tomography (CECT), on which it appears as a well demarcated tumor, 
with characteristic peripheral enhancement during the early phase with subsequent 
centripetal flow during the portal venous phase. A heterogeneous consistency is 
usually a sign of necrosis, hemorrhage, or fibrosis [5].
Multiphasic computed tomography (CT) has a detection rate of 100% for 
adenomas, which is however different per type of examination: nonenhanced 86%, 
hepatic arterial-dominant phase (HAP) 100%, portal venous-dominant phase 
(PVP) 82%, and delayed 88%. Tumor margins are well defined by a low-attenuation 
pseudocapsule in 86% of adenomas and the surface appears smooth, without 
lobulated contour, in 95%. Tumor fat and calcifications are uncommon (7%, respec-
tively 5%). Other than areas of fat, hemorrhage, or necrosis, the adenomas show 
homogenous enhancement, especially on PVP and delayed-phase scans [39].
Figure 13. 
HA located in segment VII as shown by imaging on NECT (A), CECT—arterial phase (B), portal venous phase 
(C), parenchymal phase (D), MRI T1w (E), and T2w (F). Atoll sign characterized by a hyper intense band in 
the periphery and isodensity in the center of the lesion with respect of the surrounding liver is relevant on CT in 
portal venous phase (C). A hyperintense rim in T2 wi is described in inflammatory adenoma (arrow in F).
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MSCT technique: nonenhanced CT and enhanced triphasic CT: in arterial 
(30–35 s after the bolus tracker detection), portal venous (60–80 s after contrast 
medium injection), and equilibrium/late phases (after 3–5 min). 1.5 ml/kg of 
nonionic iodinated contrast material is injected into an antecubital vein with a rate 
of 3 ml/s using a power injector.
CT findings are depending on HA subtype. On nonenhanced CT (NECT), hem-
orrhage within tumor is seen on as hyperdense foci, intratumoral lipid as hypodense 
foci (negative density), and focal coarse calcifications are rarely seen (Figure 14). 
On contrast-enhanced (CECT), encapsulation is present in ~20% of HAs, best seen 
on the late phase (Figure 14). Hypervascularity is most intense and persistent in 
inflammatory subtype of HA (Figure 15).
CT is most useful in distinguishing a HA from other liver tumors or lesions: (1) 
focal nodular hyperplasia which has a characteristic central star-shaped hypodense 
scar, (2) hemangiomas with their peripheral enhancement on arterial phase and 
progressive centripetal fill-in pattern, (3) liver cell carcinoma which has a par-
ticular wash-in, wash-out pattern, and (4) singular liver metastases with no fat or 
hemorrhage.
6.1.3 Magnetic resonance imaging (MRI)
6.1.3.1 MRI technique
Unenhanced conventional sequences: T2w is useful in detection of focal liver 
lesions. T2* is important in the evaluation of iron content and chemical shift artifact 
sequences; T1 in/out of phase is important to delineate steatosis or intralesional lipo-
matous content; ssFSE short TE/long TE makes differentiation between cysts and 
solid mass; and diffusion is the most sensitive sequence for liver lesion detection.
Contrast enhanced T1: multiphase dynamic 3D acquisitions without and with 
intravenous injection of 0.1 ml/kgbw of extracellular or liver-specific contrast para-
magnetic agents (Gd-EOB-DTPA) in arterial phase (AP): detection of hypervascular 
lesions, portal venous phase (PVP), late phase (LP), and hepatobiliary phase (HBP).
Imaging key features in HAs are: hypervascularity, fat content, hemorrhage, 
and encapsulation. MRI shows some elements better than CT (lipid and hemor-
rhage). HA shows no substantial uptake or retention in contrast enhanced MRI with 
Gadoxetate (Primovist). MRI features for adenomas are distinct from FNH. T1WI: 
mass with heterogeneous signal intensity; increased signal intensity (due to fat or 
recent hemorrhage); decreased signal intensity (necrosis, calcification, old hemor-
rhage) T1 + C: heterogeneous, hypervascular liver mass with foci of fat or hemor-
rhage in a young woman.
Figure 14. 
NECT with large liver mass with central calcifications, small lipomatous inclusions, solid components and 
necrosis (A), CECT—arterial phase (B), portal venous phase (C), and parenchymal phase (D).
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6.1.3.2 MRI evaluation
Some MRI findings of HAs are similar to CT findings, but MRI is usually more 
sensitive in detecting fat from hemorrhage. The appearance of HAs on MRI is highly 
variable, especially in T1, but if contrast medium is used, then it may be better 
characterized, showing early arterial enhancement and becoming nearly isointense 
to liver on delayed images.
On T1-weighted images (T1wi), HA appears as a heterogeneous signal inten-
sity mass. The increased signal of HA is due to fat and recent hemorrhage, and the 
decreased signal intensity is due to necrosis, calcification, or old hemorrhage. A 
fibrous pseudocapsule may be seen in HA as a hypointense rim. In T2wi, the mass 
appears heterogeneous; increased signal intensity corresponds to old hemorrhage 
or necrosis, and the decreased signal intensity is due to the fat or recent hemor-
rhage. The peripheral rim (fibrous pseudocapsule) in HA appears hypointense 
in liver parenchyma (Figure 16). After contrast injection (T1wi + C) in arte-
rial phase, adenomas are heterogeneous hypervascular masses (inflammatory 
HA+++) and in delay phase a pseudocapsule, which is hyperintense comparative 
to the normal liver, can be seen. After Gadoxetate-enhanced MR (Gd-EOB-
DTPA), in HA there is no substantial contrast uptake or retention on hepatobili-
ary phase [40].
Figure 15. 
CT evaluation: liver adenoma with central necrotic area and encapsulation (arrow).
Figure 16. 
MRI evaluation: liver adenoma with central necrotic area and pseudocapsule hyperintense to the surrounding 
liver (arrow).
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MRI with hepatobiliary agents is an important tool not only in differential sub-
type definition but even in surveillance with early identification of complications 
and discovery of some signs of HA malignant degeneration [41]. Lesion enlarge-
ment and heterogeneity of signal intensity and of contrast enhancement are signs 
of malignant transformation [42].
Imaging recommendations: the best imaging tool is represented by Gadoxetate-
enhanced MRI including multiphase and hepato-biliary phase acquisition [43]. The 
best sequence to evaluate fat into HA is T1wi with in and opposed TE.
6.1.3.3 Classification of HAs based on imaging examinations
MRI is the imaging modality of choice for characterization of HA subtypes 
[22]. Inflammation, abnormal rich vascularization, peliotic areas, and abundant 
fatty infiltration are pathologic findings differently present in the HA subtypes at 
multiparametric MRI [41].
HNF1A-mutated adenoma (H-HA): on MRI, the diffuse and homogenous fat 
deposition within HA-H determines a specific imaging pattern: on T1-weighted 
Gradient-Echo MR, it is hyper- or isointense, with diffuse signal drop-off with 
the use of chemical shift sequence (Figure 17). On T2-weight MR, images appears 
isointense to slightly hyperintense. Gadolinium-enhanced T1-weighted MR images 
show moderate enhancement in the arterial phase, with no persistent enhancement 
in the portal venous and delayed phases. Generally, its size is less than 5 cm, and 
there are minimal risks of bleeding and malignant transformation [22]. At multi-
detector CT, macroscopic fat deposits can be identified and establish the diagnosis 
of H-HA. On CEUS, it has iso- to moderately increased vascularity, mixed filling in 
the arterial phase after contrast and isoechoic appearance in the portal venous and 
delayed phases.
β-catenin-mutated hepatic adenoma (β-HA): there are no distinctive patterns 
established on MRI, multidetector CT, or CEUS, but they usually are hypervascular 
with evidence of hemorrhage or necrosis within tumor. Besides the fact that has 
the highest risk of malignant transformation (> 10%), it may mimic hepatocellular 
carcinoma with strong enhancement during arterial phase and with portal venous 
wash-out.
Inflammatory hepatic adenoma (IHA): includes those previously called “telan-
giectatic HA.” It has specific patterns on MRI due to less fat content, sinusoidal 
dilation, peliotic areas, and abnormal vessels. On T1-weighted Gradient-Echo 
MR images, it is depicted as isointense or mildly hyperintense, without signal 
drop-off with the use of chemical sequence, and on T2-weighted MR images, it 
becomes bright (diffusely hyperintense). On Gadolinium-enhanced T1-weighted 
MR images, it shows intense enhancement during arterial phase that persists in 
Figure 17. 
HNF1A-mutated HA: diffuse lipid deposition within HA best seen using T1 with TE in and out of phase 
(arrow).
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the portal venous and delayed phases (Figure 18). The atoll sign is specific for IHA 
and may be due to sinusoidal dilatation. In up to 30% of cases, there is evidence of 
hemorrhage, and a 10% likelihood of malignant degeneration is estimated. At mul-
tidetector CT, IHA is depicted as heterogeneously hyperattenuating mass in NECT 
and in CECT shows enhancement features similar to those at MRI. At CEUS, it has 
arterial vascularity with centripetal filling, a sustained enhanced rim and central 
wash-out in the late venous phase.
Unclassified hepatic adenoma (U-HA) does not fit other profiles of HA subtypes.
6.1.3.4 Differential imaging diagnostic of adenomas
Hepatocellular carcinoma (HCC) may be hard to distinguish on imaging or 
pathology. Biliary, vascular, nodal invasion and metastases of HCC typically occur 
in older, cirrhotic men [42, 45]. Adenoma occurs in young, healthy women. 
Fibrolamellar HCC is shown as a large, lobulated mass with scar and septa inside. 
Vascular, biliary invasion and metastases are common. 
Focal nodular hyperplasia (FNH) is depicted on MRI + C in arterial phase as 
a homogeneously enhancing mass and in all other phases as an isodense mass 
comparative to normal liver. In T2WI, a scar is typically seen as hyperintense. On 
delayed phase MR, FNH uniformly retains Gadoxetate [44, 45]. Gadoxetic acid-
enhanced MRI can differentiate between HA and FNH with a high sensitivity and 
specificity [46]. 
Hypervascular metastases are usually multiple. The primary tumor (i.e., thy roid, 
breast, kidney, or endocrine) must be searched for. CT + C or MRI + C in arterial 
phase shows heterogeneous enhancement. In portal and delayed phases, hypervas-
cular metastases may appear isodense, hypodense, or hypointense. 
6.2 Nuclear medicine studies
Most HAs have a decreased uptake of Gallium and colloid, early and retained 
uptake of hepatobiliary agents, and no uptake on PET scanning.
If radiological studies cannot distinguish HA from HCC and FNH, a combination 
of radionuclide imaging, including technetium (99mTc)-sulfur colloid sulfur-colloid, 
Figure 18. 
Inflammatory liver adenoma: hyperintensity T2 wi and hypervascularity of the liver mass through the late AP, 
and discreetly hyperintense in portal and late phase.
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Ga, and technetium-99 pyridoxyl-5-methyltryptophan (PMT) uptake may help estab-
lish the correct diagnosis [47]. Most adenomas do not take up technetium Tc-99m 
sulfur colloid so they appear as a “cold” spot in the parenchyma of the liver. This 
examination is not particularly good in diagnosing an adenoma but in distinguish-
ing one from a FNH, which shows equal or greater uptake of the radiolabeled agent 
compared with surrounding liver [48]. 99mTc-labeled DISIDA (dimethyliminoacetic 
acid) liver scintigraphy has also been used by some authors for diagnosis of HA [47].
Positron emission tomography (PET) scanning with fluorine-18-fluorodeoxy-
glucose (18FDG) is useful in differentiating HAs from malignant tumors, because 
malignant tumors show uptake of 18FDG but not benign tumors, with some excep-
tions like inflammation and abscess.
Although CEUS, CT, MRI, and nuclear studies help in characterization of 
hepatic lesions as adenomas, the findings sometimes are nonspecific, and biopsy 
and/or resection may still be necessary.
6.3 Detection of malignant transformation
The pathogenesis of malignant transformation of hepatocellular adenoma 
is still poorly understood. Some light was recently shed on the mechanisms of 
hepatocarcinogenesis, which suggest the importance of telomerase reverse tran-
scriptase (TERT) promoter mutations beside the early event of β-catenin mutation. 
Apparently, only the β-catenin mutations that occur on exon 3 and not those on 
exon 7–8 are involved in malignant transformation of HA [49]. It still remains 
unclear if hepatocellular carcinoma emerges from hepatocellular adenoma or if the 
lesions are coincident. Malignant transformation of hepatocellular adenoma has 
been reported in 4% of women and 47% of men with HA [50]. The risk of malig-
nancy is very high for β-HA, which is most frequently associated with glycogenosis 
type 1, androgenic hormone intake (many of these tumors expressing androgen 
receptors in men), and familial polyposis. It is important to remind that no HA sub-
type is devoid of risk of malignant transformation. Men are predisposed to hepato-
cellular carcinoma regardless of etiology, and for this reason, surgical treatment is 
strongly recommended for male patients diagnosed with HA. For women, an older 
age (50 years or older) or a younger age (15 years or less) is a risk factor for malig-
nant degeneration that must be taken into account to refer these patients to surgeon 
for resection or at least to a hepatologist for very close and careful surveillance.
At present, no clinical assessment can distinguish between HA and degenerated 
HA, and no rules for surveillance of HA in both sexes are clearly defined according to 
subtypes. The methods and the periodicity of following these patients are variable. 
Radiological assessments could include CEUS, multidetector raw CT, and dynamic 
MRI. CEUS allows more sensitive recognition and specific exclusion of malignancy 
compared with CT and dynamic MRI and has the advantage that can be repeatedly 
performed without the risk associated with allergic reactions or radiation exposure. 
Moreover, MRI has the disadvantage that cannot be performed everywhere in the 
world because the technical skills and expertise are very much geographically depen-
dent. Two main features must be taken into consideration at reassessment of these 
patients with HA: the size of the tumor and, more important, the hemodynamic 
changes that precede the tumor growth [50]. Malignant degenerations are considered 
when the tumor was first iso-attenuated when compared with normal liver during the 
nonenhanced and delayed phases and appeared homogenous in the early phase but, 
at a later examination, it becomes enhanced in the early phase and hypo-attenuated in 
the delayed phase. Also, the presence of a nodule within a nodule during the arte-
rial phase is known as a sign of malignancy. β-HA often has cytological atypia and 
pseudoglandular pattern, and it is sometimes almost impossible to identify HCC.
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7. Management and current guidelines
The surgeons must be convinced that HA subtypes are important for the man-
agement of the patients. From now on, a diagnosis of HA cannot be conceived 
without group classification. The number and location of HA play a great role 
in management, but various clinical conditions such as age, sex, etiology, back-
ground liver, or comorbidities must be taken into consideration. Other aspects 
also play a role in decision making, like where the patient lives, the degree of his/
her anxiety, and cost of surveillance. The management of patients with HA must 
be planned by a complex team formed by surgeons, hepatologists, pathologists, 
radiologists, gastroenterologist, molecular biologists, and geneticists.
There are no clear guidelines for the management of HA, because the treatment 
depends on many factors such as HA size, number, localization, gender, age, pres-
ence of symptoms, and complications.
In young women treated with contraceptive pills, asymptomatic lesions under 
5 cm in diameter should be kept under close observation with CT/CEUS repeated 
every 6 months [51] and repeated alpha-feto-protein, all the while ceasing to use 
contraceptive pills [52]. Any modification in imaging suggesting a malignant trans-
formation or an increase in the serum tumor marker should lead to liver resection. 
There are some authors who advocate resection of adenomas of any size given their 
risk of malignization and bleeding, if the resection can be performed with accept-
able risk. The facts that surgical excision guarantees a definitive diagnosis and 
long-term cure favor the universal indication of surgery for HA [53].
7.1 Surgical resection
The indications for surgery in nonemergent cases are: HA > 5 cm, female patients 
taking oral contraceptives with HA > 3 cm [47], HA with growing size, HA with 
HCC or dysplastic foci, β-catenin-activated HA, imaging features of malignant 
transformation, increased serum alpha fetoprotein, HA in males regardless of the 
tumor size, HA in GSD, symptomatic patients, or when malignancy cannot be 
excluded [54]. The type of resection depends mainly on number, size, histological 
type, and localization of HA. The resection techniques vary from simple enucleation 
to liver transplantation [55]. Liver resection for HA can be anatomic or nonanatomic. 
Anatomic resections reported in the literature for HA refer to minor hepatectomies 
that imply the removal of the tumor with one or two segments of the liver [56], but 
also major hepatectomies like left and right hemihepatectomy, mesohepatectomy 
[57], and left or right extended hepatectomy [26, 58]. Nonanatomical resections are 
wedge resections [59]. Enucleation seems to be a choice for such benign tumor, but 
is not advisable due to the risk of remnant tumor that can cause tumor recurrence or, 
worse, malignant degeneration, especially for β-catenin HA. It was speculated that 
the classical 1 cm oncological safety margin could be lowered to 0.5 cm for HA. The 
safety margin at the edge of resection is mandatory, if any suspicion of HCC exists.
Surgery in elective cases is less than 1% and most tumors can be operated 
laparoscopically, with significant advantages [59–61]. A better cosmetic result, 
a shorter hospitalization (4 days) with early return to normal life, and a lower 
incisional rate are the main advantages that laparoscopy has comparative with 
open approach. However, laparoscopy should be performed only in specialized 
centers with extensive experience in both hepatic and laparoscopic surgery. 
The first non-anatomical laparoscopic liver resection for HA reported by Ferzli 
et al. [62] in 1995 was followed one year later by the first anatomic laparoscopic 
resection for HA performed by Azagra et al. [63]. Pure laparoscopic procedure 
can be performed for HA with no mortality and reduced morbidity even in 
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hemodynamic stable patients with ruptured HA [61]. Moreover, some surgeons 
consider laparoscopic surgery the standard of care for the treatment of HA [59]. 
Hand-assisted or “hybrid” techniques are also optional approaches [64] and the 
parietal incision is later used for specimen retrieval. In pure laparoscopic surgery, 
the specimen is retrieved through a Pfannenstiel incision even when the tumor is 
as large as 180 mm [61].
Pringle maneuver can be of great use to minimize the intraoperative blood loss and 
it is used by surgeons both in laparotomy and laparoscopy. Some authors consider it 
unnecessary for laparoscopic left lateral sectionectomy [60]. Instead, others perform 
the maneuver for both atypical and anatomical resections. Laparoscopy is restricted 
by the localization of HA involving segments VII and VIII. The half-Pringle maneuver 
was associated for right posterior sectionectomy and resulted in less bleeding [65].
Total vascular exclusion of the liver is routinely recommended in high dorsal 
resections for HA [66].
Intraoperative blood transfusion is rarely needed and generally is performed 
in case of ruptured bleeding adenoma. Conversion of laparoscopy to laparotomy 
should be considered just in case of too much bleeding and difficulties for the 
anesthesiologist to stabilize the patient.
The high rates of mortality and morbidity previously reported after liver resec-
tion for bleeding HA are recently denied by new evidences [30]. Emergency resec-
tion of ruptured HA has a mortality rate of 5–10%, whereas elective surgery has 
a mortality rate of less than 1% [67]. These results are explained nowadays by the 
availability of improved hemostatic techniques, excellent anesthesia support, and 
postoperative intensive care. In the past, in the presence of signs of hemorrhagic 
shock, the mortality was as high as 20% for resection [68]. At present, the mortality 
for such patients trends toward zero. Nonsurgical strategies such as arterial embo-
lization or gauze packing have been recommended in order to stabilize the patient 
and delay resection to an elective setting. There are situations when intraperitoneal 
bleeding from a ruptured adenoma is self-limited and a laparotomy is done just 
for biopsy. A recent bleeding adenoma does not necessarily need resection. After 
this acute bleeding, some of these tumors regress, others are stationary, and few 
rebleed. Transarterial embolization (TAE) can not only stabilize the patient but 
also obtain complete avoidance of surgical intervention. Sometimes, repeated 
embolization is needed to achieve hemostasis. However, liver resection remains the 
best means to achieve hemostasis and also to obtain a thorough histology.
7.2 Liver transplantation
Liver transplantation is an extraordinary choice in a few selected patients, 
with multiple HAs, giant HAs [69], or recurrent adenomas that are not technically 
resectable [70]. Those HAs considered unresectable are either in close proximity 
to major vascular structures or the liver hilum or less than 20% of viable hepatic 
parenchyma remains after resection. Liver transplantation for recurrent HA is a 
more technically demanding procedure if compared to the cases with chronic liver 
disease due to the presence of postoperative adhesions that must be divided before 
reaching the liver and also due to difficulties in liver implantation when at least a 
major hepatic vein and hepatic pedicle are absent after major hepatectomy [70]. 
Transplanted liver is generally harvested from a cadaveric donor but living liver 
transplantation has also been reported [71]. Due to an expanding armamentarium 
and experience in angiographically controlling bleeding from a ruptured HA, liver 
transplantation as an ultimate life-rescue therapy remains exceptionally rare, being 
reported for spontaneous intra-partum rupture of hepatocellular adenoma [72] 
(Algorithm 1).
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Algorithm 1. Management in hepatic adenoma.
7.3 Management of liver adenomatosis
The management of cases with liver adenomatosis is cumbersome. All women 
with adenomatosis must discontinue exogenous hormone therapy and should avoid 
pregnancies. In the massive pattern of adenomatosis, if larger lesions comprise a 
single lobe, a hemihepatectomy or more limited hepatic resection (Figure 19) could 
be a wise choice. Laparoscopic left lateral sectionectomy can be a good approach for 
those patients expecting a future liver transplantation [73] (Algorithm 2).
Algorithm 2. Management in liver adenomatosis.
Even the resection of only the complicated nodule (i.e., hemorrhagic liver 
nodule) seems appropriate as the first step toward enlisting for liver trans-
plantation. Multiple resections are the preferable options in patients with liver 
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adenomatosis, unless technically impossible or unsafe. Radiofrequency ablation 
or embolization in these patients was successful in some authors’ experience 
[74]. Liver adenomatosis becomes an indication for liver transplantation if there 
is evidence of malignant transformation or complications [75]. Observing these 
changes is possible only if patients are carefully followed on a regular basis with 
imaging. Liver transplantation should be considered as the last resort for patients 
with adenomatosis. Patients with GSD should undergo transplantation earlier 
than other patients with HA because the literature considers this underlying 
disease as a risk factor for malignant transformation of adenomas [72]. Like 
in transplantation for HCC, imaging diagnosis of vascular invasion should be 
considered an absolute contraindication to transplantation. So all the efforts are 
directed to early diagnose a malignant transformation of HA, and any suspicion 
of malignancy has to be rapidly confirmed by biopsy. Discussion with the patients 
with liver adenomatosis about liver transplantation must be initiated when a major 
criterion or at least 3 minor criteria are identified. The only major criterion is the 
histological proof of malignancy in at least one adenoma. The minor criteria are: 
(1) more than 2 serious (life-threatening) hemorrhages, (2) more than 2 previous 
hepatectomies, (3) β mutated or inflammatory adenomas, (4) underlying liver 
disease (major steatosis and vascular abnormalities), and (5) age > 30 years [72] 
(Figure 20).
7.4 Alternative treatment of HA
Other options of treatment include: transarterial embolization or ablation and 
radiofrequency ablation. TAE is considered as a safe and effective mini-invasive 
Figure 19. 
Upper left: massive liver adenomatosis that deforms the contour of the left lateral sector. Upper right: a left 
lateral sectionectomy is planned and a cotton loop around hepatic pedicle is placed for Pringle maneuver. 
Lower left: intraoperative aspect after left lateral sectionectomy. Lower right: sectioned surgical specimen with 
evidence of the largest HA.
21
Challenging Issues in Hepatic Adenoma
DOI: http://dx.doi.org/10.5772/intechopen.87993
procedure to be used in both elective and emergency conditions. For small lesions, 
TAE can achieve complete resolution and thus avoidance of liver surgery entirely. 
TAE may be also used as means to shrink the tumors to a size that renders them 
approachable for subsequent surgical resection [76]. TAE can reduce the size of 
large adenomas, multiple adenomas, or adenomas that are in a surgical inacces-
sible localization alleviating the symptoms and reducing the risk of perioperative 
bleeding. It has a low rate of complications (8%). These complications associated 
with TAE include post-embolization syndrome, temporary renal failure, and cyst 
formation [77]. One pyogenic abscess after TAE was also reported as a complication 
after TAE for a large HA. No sufficient data exist until now to conclude that TAE 
reduces the risk of hemorrhage or malignant transformation of residual HA, despite 
reports of a reduction in tumor size.
Radiofrequency ablation has its shortcomings, such as the need of many ses-
sions in order to destruct the tumor completely, but it may be a very good option for 
tumors that cannot be operated [78].
Medical treatment such as administration of the SRC inhibitor dasatinib or 
JAK1/2 inhibitor ruxolitinib could be a new alternative in the future [79].
7.5 Management of pregnant patient
Pregnancy is no longer considered a contraindication in hepatocellular ade-
noma less than 5 cm. Given the fact that the HA behaves as a hormone-dependent 
tumor that seems to grow or regress according to estrogen level increase or 
decrease, respectively, it is advised that patients with adenomas who contemplate 
pregnancy firstly resolve the liver tumor prior to remaining pregnant [80]. If HA 
was diagnosed in a fertile but nonpregnant woman, and if the tumor is greater 
than 5 cm or she has experienced adenoma-related complications, resection is 
indicated before pregnancy. If HA is incidentally identified during pregnancy, 
the best management varies from case to case. For the smaller lesions, a conserva-
tory approach is feasible on the condition of ultrasound follow-up every 6 weeks. 
Figure 20. 
Liver adenomatosis with a voluminous adenoma of the left liver in a 47-year-old male patient who had a liver 
transplantation. A-C. CECT of the liver with adenomatosis. D. Total hepatectomy specimen with numerous 
adenomas of various sizes, a voluminous adenoma in the left liver, and blood clots due to intratumoral 
bleeding.
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Adenomas greater than 5 cm that are discovered during pregnancy need individu-
alized approach. Surgery is recommended during second trimester to minimalize 
the risks for both the mother and the fetus. Radiofrequency has been an option 
performed during the first and second trimester [18]. Angioembolization poses 
the radiation risk to the fetus early in pregnancy and must be avoided in the first 
trimester.
Pregnancy induces not only an increased level of endogenous hormones 
but also an increased liver vascularity that puts the patient at risk for adenoma 
rupture especially in the third trimester [81]. However, a ruptured HA discovered 
during pregnancy should be immediately resected by laparotomy or laparoscopy 
[28, 82, 83].
7.6 Follow-up of the patients
The great majority of nonresected uncomplicated HA remains stable, in few 
cases disappear, and in general do not grow. There is an observation that IHA may 
disappear more rapidly.
The follow-up of the patients with H-HA and IHA with complete resection can 
be stopped few years after surgery. In case of incomplete resection and with no 
significant change in HA size during the first years, the follow-up must be contin-
ued but at longer intervals.
Instead, the patients with β-HA resected or RF ablated must be followed-up 
very closely with AFP serum level check and repeated alternating imaging (US, 
CEUS, CT, and MRI) in order to early diagnose a possible recurrence and, in a 
much worse scenario, a possible malignancy with the same positioning in the 
liver [84].
8. Conclusions
The incidence of hepatic adenoma has increased lately as a result of more 
frequent imaging investigations performed for reasons not necessarily related 
to the presence of this benign tumor. The classical profile of the patient with 
adenoma has changed as a result of the emergence of new risk factors. As a result 
of research into phenotype, genotype, and imaging and the correlations of these 
results with clinical data, it is advisable that the diagnosis of hepatic adenoma 
include the subgroup of classification, which indicates the appropriate manage-
ment of the case. The means of fitting the liver adenoma into the four subgroups 
are primarily imagistic, of which MRI has an essential role. In the case of insuf-
ficient data for the correct and complete diagnosis of hepatic adenoma, tumor 
biopsy is needed percutaneously or after tumor resection. Management of hepatic 
adenoma may mean on the one hand careful monitoring to recognize one of the 
two worrisome complications—hemorrhage and malignancy—and on the other 
hand, the treatment of the tumor, which may be asymptomatic or symptomatic, 
uncomplicated or complicated. In the elective cases, surgical resection remains the 
gold standard with a clear tendency toward laparoscopic approach in specialized 
centers, but in emergency cases caused by adenoma rupture, interventional arte-
riography has gained a net advantage over surgery. For rare cases of recurrent or 
extremely bulky hepatic adenomas, for which surgery is not feasible, but also for 
cases of liver adenomatosis on certain criteria, liver transplantation from cadav-
eric or living donor has become a reality. Careful monitoring of post-treatment 
patients should be continued and adapted according to the therapeutic outcomes 
and histopathology of the hepatic adenoma.
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